ArticleAllergy2016
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Article in Allergy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00044304 (Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet journal of rare diseases · 2023Guideline
- Eosinophils and eosinophil-associated diseases: An update.The Journal of allergy and clinical immunology · 2018Pooled it
- Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practice · 2025Trial
- Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.British journal of haematology · 2024Trial
- Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.Frontiers in immunology · 2022Trial
- Benralizumab forThe New England journal of medicine · 2019Trial
- Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.The journal of allergy and clinical immunology. In practiceTrial
- Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.The journal of allergy and clinical immunology. In practiceTrial
- Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.The journal of allergy and clinical immunology. Global · 2026Article
- Tracking Public Interest in Rare Diseases and Eosinophilic Disorders in Germany: Web Search Analysis.JMIR infodemiology · 2025Article
- Imatinib is effective in some PDGFRA/B-negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms.British journal of haematology · 2024Article
- Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis.Cancers · 2024Review
- Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.The journal of allergy and clinical immunology. In practice · 2023Article
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- [Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].Zeitschrift fur Rheumatologie · 2023Article
- False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.Acta haematologica · 2023Article
- Uncommon causes of chronic cough associated with airway eosinophilia.Journal of thoracic disease · 2021Article
- Review
- Cough in hypereosinophilic syndrome: case report and literature review.BMC pulmonary medicine · 2020Review
- Contributions of Eosinophils to Human Health and Disease.Annual review of pathology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundWith the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES).
methodsSubjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT00044304: registered at clinicaltrials.gov). The primary outcome was an eosinophil count <1.5 × 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. A retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily ≥ 1 month) were classified according to the criteria used in the prospective study.
resultsOverall, imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of ≥ 4 myeloid features was the sole predictor of response. After ≥ 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remain in remission off therapy for a median of 29 months (range 14-36).
conclusionsClinical features of MHES predict imatinib response in PDGFRA-negative HES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.